Monmouth, NJ based CytoSorbents Corporation (CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit–with the goal of preventing or treating multiple organ failure in life-threatening illnesses, announced that it will sponsor a research symposium entitled: “SIRS and SEPSIS – New Therapy with CytoSorb®” at the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2014) in Brussels, Belgium and scheduled for Wednesday, March 19, 2014 from 6:15 – 7:45 PM in the ARC room of the Square – Brussels Meeting Center.
Physicians are to discuss the application of CytoSorb® extracorporeal cytokine reduction in sepsis and other inflammatory conditions, such as cardiac surgery.
Dr. Herwig Gerlach (Berlin, Germany): “Overshooting the inflammatory response – The Root of all Evil?”
Dr. John Kellum (Pittsburgh, USA): Blood purification in SIRS and Sepsis: A new paradigm”
Dr. Michael Quintel (Gottingen, Germany): Clinical Experience: Severe sepsis/ septic shock and CytoSorb® therapy
Dr. Karl Trager (Ulm, Germany): Clinical Experience: Post-Cardiopulmonary Bypass SIRS and CytoSorb® therapy.
In addition, attendees can visit CytoSorbents’ exhibit booth in the Silver Foyer, Booth S.01 from March 18-21, 2014 to learn more about CytoSorb® immunotherapy for critical illnesses and how, through cytokine reduction, it targets a reduction of the potentially deadly systemic inflammatory response syndrome (SIRS) in order to prevent or treat organ failure and improve clinical outcomes.
The International Symposium on Intensive Care and Emergency Medicine (ISICEM) is organized by the Departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Universite Libre de Bruxelles, in association with the Belgian Society of Intensive Care and Emergency Medicine. This annual conference was started in 1980 and has become established as one of the largest in its field, now attracting more than 6,000 participants from countries worldwide. The objectives of this four-day symposium are to provide participants with an up-to-date review of the most recent, clinically relevant, developments in research, therapy, and management of the critically ill. The meeting is open to all physicians, nurses, and other health professionals with an interest in critical care or emergency medicine.
Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company’s flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the “cytokine storm” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others.
CTSO is currently trading in the $.20 per share range with a 3-month average trading volume of 2,032,850/day. The 52 range is $.08-$.35 per share.
The company announced in March 2014 that it had raised $10,200,000 from institutional investors via Bean Capital agented deal.
For more information about CytoSorbents Corporation (CTSO) please visit a company dedicated page at the Vista Partners’ website by clicking this link where you can find interesting commentary, links to SEC filings, the company’s website, related video, the latest company presentation/corporate annual report, the latest company and industry news, a FREE Report & more.
Please remember that the FREE Vista Partners’ Monthly Macroeconomic Newsletter for March is available at the Vista Partners’ website www.vistapglobal.com. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary that reaches across adtech, biotech, energy, healthcare, consumer spending, natural resources, technology, entertainment, sports & more . Anyone can receive the Vista Partners’ Newsletter automatically via email each month for FREE once one takes a few seconds to sign in to the Vista Partners website at www.vistapglobal.com.
The post A Vista Partners’ Commentary “Critical Care Immunotherapy Co. CytoSorbents (CTSO) Sponsoring Research Symposium at ISICEM 2014 Titled “SIRS and SEPSIS – New Therapy with CytoSorb®” March 19th in Brussels, Belgium” appeared first on Vista Partners.